Results 141 to 150 of about 64,954 (254)

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Analytical similarity as the primary determinant of monoclonal antibody development: toward evidence-efficient regulatory frameworks. [PDF]

Front Drug Deliv
Niazi SK.
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [PDF]

Front Immunol
Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, He P, Liu R, Zhang J, Wang K, Han R, Huangfu H.   +11 more
europepmc   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci   +9 more
wiley   +1 more source

Strain-specific propagation of variant Creutzfeldt-Jakob disease prions in humanized neural cells. [PDF]

Proc Natl Acad Sci U S A
Rayner MLD, Arora P, Linehan JM, Ros H, Nihat A, Argentina F, Preston C, Schmidt C, Ribes JM, Klöhn PC, Mead S, Brandner S, Collinge J, Jat PS.   +13 more
europepmc   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

Antibodies to watch in 2026. [PDF]

MAbs
Crescioli S, Kaplon H, Chenoweth A, Hsu YS, Pinto K, Kapoor V, Reichert JM.   +6 more
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, Volume 78, Issue 7, Page 1393-1402, July 2026.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review. [PDF]

Front Immunol
Aureli A, Lanzilli G, Boccadamo Pompili SV, Spagnoli GC, Sconocchia G, Caratelli S.   +5 more
europepmc   +1 more source